NUTX (Nutex Health) 3-Year EBITDA Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NUTX Nutex Health Inc NUTX
75 GF Score
Price $193.35
GF Value $82.60
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Nutex Health 3-Year EBITDA Growth Rate?

Nutex Health NUTX -0.29% 75 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates NUTX with a GF Score™ of 75/100 and a GF Value™ of $82.60 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 526 Healthcare Providers & Services companies, Nutex Health ranks worse than 190113.88% on this metric.

Nutex Health's EBITDA per Share for the three months ended in Jun. 2026 was $18.10.

During the past 12 months, Nutex Health's average EBITDA Per Share Growth Rate was 46.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Nutex Health was -14.10% per year. The lowest was -14.10% per year. And the median was -14.10% per year.


Nutex Health  (NAS:NUTX) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Nutex Health 3-Year EBITDA Growth Rate Related Terms


NUTX vs USPH, AMN, GMRS: 3-Year EBITDA Growth Rate Comparison

For the Medical Care Facilities subindustry, Nutex Health's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nutex Health 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Nutex Health's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Nutex Health's 3-Year EBITDA Growth Rate falls into.


NUTX
75GF Score
Nutex Health Inc NUTX
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nutex Health 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Nutex Health (NUTX) has a 3-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nutex Health and its competitors. According to the industry distribution chart, Nutex Health ranks #999999 out of 526 companies in the Healthcare Providers & Services industry.
Is Nutex Health's 3-Year EBITDA Growth Rate too high?
Nutex Health's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Nutex Health ranks #999999 out of 526 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Nutex Health has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nutex Health's 3-Year EBITDA Growth Rate compare to USPH and AMN?
According to the Healthcare Providers & Services industry distribution chart, Nutex Health ranks #999999 out of 526 companies for 3-Year EBITDA Growth Rate. This places Nutex Health in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.05, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nutex Health and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nutex Health's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nutex Health stock overvalued right now?
Based on GuruFocus' analysis, Nutex Health (NUTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $82.60, compared to a current price of $193.35 — trading 134.1% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. Nutex Health's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Nutex Health (NUTX), the current 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nutex Health (NUTX) Overvalued in 2026?

Based on GuruFocus' analysis, Nutex Health stock appears to be overvalued. The current stock price of $193.35 is trading 134.1% above its estimated GF Value™ of $82.60. GuruFocus considers Nutex Health to be Significantly Overvalued.

Key valuation signals for NUTX:

  • 3-Year EBITDA Growth Rate: 0.00%
  • GF Value™: $82.60 vs. price of $193.35 (134.1% above fair value)
  • GF Score™: 75/100 with 6 warning signs

No single metric tells the full story. See the NUTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nutex Health Business Description

Other Exchanges 5LF:Germany
Address 1776 Yorktown Street, Suite 700, Houston, TX, USA, 77056
Nutex Health Inc is a physician-led, healthcare services and operations company with various hospital facilities in the U.S. states (hospital division), and a primary care-centric, risk-bearing population health management division. The company has three segments: the hospital division, the PHM division, and the real estate division. The hospital division implements and operates health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management (PHM) division owns and operates provider networks such as independent physician associations (IPAs). The Real Estate Entities own the land and hospital buildings which are leased to its hospital entities. The majority of the revenue is derived from the Hospital division.
75GF Score

Get the complete analysis for NUTX

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$193.35
Price
$82.60
GF Value